Filing Flows › Companies › Ionis Pharmaceuticals › Report card
Ionis Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate4 of 4 reports beat the EPS estimate
Ionis Pharmaceuticals (IONS) beat the analysts' EPS estimate in 4 of its last 4 reports (100%), by +40.0% on average. On report days the stock moved 4.2% in either direction on median (largest 5.7%), rising 50% of the time; after a beat it rose 50% of the time. Next report: Nov 9, 2026, analysts expect EPS −$0.93.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$0.88 | −$0.42 | +51.7% | −$0.69 | $268M | -3.7% | -3.8% |
| Q1 2026 | Apr 29, 2026 | −$0.78 | −$0.30 | +60.9% | −$0.56 | $246M | +4.2% | +3.2% |
| Q4 2025 | Feb 25, 2026 | −$1.22 | −$1.15 | +5.6% | −$1.41 | $203M | -5.7% | -6.0% |
| Q3 2025 | Oct 29, 2025 | −$1.05 | −$0.61 | +41.8% | −$0.80 | $157M | +0.8% | +1.9% |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 4 reports the stock moved 4.2% on median on the day (close to close), the largest move 5.7%.
After a beat the stock rose 50% of the time (4 beats).
The next report: what to expect → Ionis Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.